Boston, MASSACHUSETTS33 Active Studies

Osteogenesis Imperfecta Clinical Trials in Boston, MASSACHUSETTS

Find 33 actively recruiting osteogenesis imperfecta clinical trials in Boston, MASSACHUSETTS. Connect with local research sites and explore new treatment options.

33
Active Trials
32
Sponsors
4,774
Enrolling

Recruiting Osteogenesis Imperfecta Studies in Boston

RecruitingBoston, MASSACHUSETTSNCT06323824

Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.

The purpose of this clinical trial is to compare the effectiveness of office-based methadone with pharmacy administration and/or dispensing to office-based buprenorphine for the treatment of opioid us...

600 participants
Yale University
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06563895

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different orga...

582 participants
Eidos Therapeutics, a BridgeBio company
View Study Details
RecruitingBoston, MASSACHUSETTSNCT05429632

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

This is a multi-center, randomized, double-blinded, placebo controlled trial....

366 participants
Priothera SAS
View Study Details
RecruitingBoston, MASSACHUSETTSNCT05005975

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

To evaluate the long-term safety and tolerability of oral dersimelagon....

301 participants
Mitsubishi Tanabe Pharma America Inc.
View Study Details
RecruitingBoston, MASSACHUSETTSNCT04067336

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies. In the Main Study (including Phase 1a, Pha...

263 participants
Kura Oncology, Inc.
View Study Details
RecruitingBoston, MASSACHUSETTSNCT04256317

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) us...

236 participants
Taiho Oncology, Inc.
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06051890

Assessing Optimal XRB Initiation Points in Jail

This application describes a 3-year, randomized controlled trial. Eligible, consenting adults (N=200) with existing sublingual buprenorphine (SLB) prescriptions who enter Middlesex County House of Cor...

200 participants
NYU Langone Health
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06788535

Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

The purpose of this Phase 3, open label, single dose imaging study is to evaluate the efficacy and safety of I-124 evuzamitide (radioactive dye) for diagnosing Cardiac Amyloidosis in participants with...

200 participants
Sharmila Dorbala
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06393712

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patient...

200 participants
Alnylam Pharmaceuticals
View Study Details
RecruitingBoston, MASSACHUSETTSNCT03593759

Cardiac Sarcoidosis Randomized Trial

Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active cli...

194 participants
Ottawa Heart Institute Research Corporation
View Study Details
RecruitingBoston, MASSACHUSETTSNCT04801797

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

This research is being done to assess the therapeutic activity of a promising combination (azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in induction-eligible patients with ac...

172 participants
Massachusetts General Hospital
View Study Details
RecruitingBoston, MASSACHUSETTSNCT05503264

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis....

152 participants
Hoffmann-La Roche
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06910358

Study of Bitopertin in Participants With EPP or XLP (APOLLO)

The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are: * Whether bitopertin incre...

150 participants
Disc Medicine, Inc
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06630234

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module...

120 participants
Deciphera Pharmaceuticals, LLC
View Study Details
RecruitingBoston, MASSACHUSETTSNCT05972551

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

The primary objective of this study is to evaluate the effect of romosozumab treatment for 12-months compared with bisphosphonate(s) on the number of clinical fractures at 12-months; the number of any...

106 participants
Amgen
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06007690

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melano...

100 participants
Aura Biosciences
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06158854

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by c...

76 participants
AbbVie
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06456463

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azaci...

76 participants
Stemline Therapeutics, Inc.
View Study Details
RecruitingBoston, MASSACHUSETTSNCT05520567

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster. Therefore, chemotherapy is les...

70 participants
Astellas Pharma Global Development, Inc.
View Study Details
RecruitingBoston, MASSACHUSETTSNCT05955261

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

This is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients with newly diagnosed acute myeloid leukemia ...

70 participants
St. Jude Children's Research Hospital
View Study Details
RecruitingBoston, MASSACHUSETTSNCT05772546

Avatrombopag vs. Placebo for CIT in GI Malignancies

The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (...

60 participants
Hanny Al-Samkari, MD
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06621251

Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection

TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making pathogens substantially more susceptible to established antibiotic treatmen...

60 participants
Trellis Bioscience LLC
View Study Details
RecruitingBoston, MASSACHUSETTSNCT05451771

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (d...

53 participants
Rajshekhar Chakraborty, MD
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06660368

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measur...

52 participants
H. Lee Moffitt Cancer Center and Research Institute
View Study Details
RecruitingBoston, MASSACHUSETTSNCT05407441

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

This research study involves a combination of three drugs given together as a possible treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, epithelioid sarcoma, chordoma or other ...

49 participants
Susan Chi, MD
View Study Details
RecruitingBoston, MASSACHUSETTSNCT04925479

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib fro...

44 participants
Novartis Pharmaceuticals
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06208748

SARC044: a Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST

This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib....

40 participants
Sarcoma Alliance for Research through Collaboration
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06097832

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL)....

40 participants
Nexcella Inc.
View Study Details
RecruitingBoston, MASSACHUSETTSNCT05796570

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

The purpose of this study is to examine if it is feasible to administer decitabine and filgrastim after allogenic hematopoietic stem cell transplant (HCT) in children and young adults with myelodyspla...

37 participants
Franziska Wachter
View Study Details
RecruitingBoston, MASSACHUSETTSNCT05145816

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

The goal of this study is to test the safety of drug, Belantamab Mafodotin, and see what effects (good and bad) it has on people who take it and amyloidosis, and to determine the most effective dose o...

37 participants
University of Texas Southwestern Medical Center
View Study Details
RecruitingBoston, MASSACHUSETTSNCT05668962

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-ref...

30 participants
Massachusetts General Hospital
View Study Details
RecruitingBoston, MASSACHUSETTSNCT04321954

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This resea...

30 participants
Massachusetts Eye and Ear Infirmary
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06284486

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML....

8 participants
M.D. Anderson Cancer Center
View Study Details

About Osteogenesis Imperfecta Clinical Trials in Boston

Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.

There are currently 33 osteogenesis imperfecta clinical trials recruiting participants in Boston, MASSACHUSETTS. These studies are seeking a combined 4,774 participants. Research is being sponsored by Yale University, Eidos Therapeutics, a BridgeBio company, Priothera SAS and 29 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Osteogenesis Imperfecta Clinical Trials in Boston — FAQ

Are there osteogenesis imperfecta clinical trials in Boston?

Yes, there are 33 osteogenesis imperfecta clinical trials currently recruiting in Boston, MASSACHUSETTS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Boston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you about next steps.

Are clinical trials in Boston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boston studies also compensate for your time and travel.

What osteogenesis imperfecta treatments are being tested?

The 33 active trials in Boston are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.

Data updated March 2, 2026 from ClinicalTrials.gov